Department of Pathology, Stanford University, Stanford, CA, USA.
Mod Pathol. 2011 Mar;24(3):425-9. doi: 10.1038/modpathol.2010.196. Epub 2010 Nov 19.
Brachyury is recognized as a specific marker for notochord-derived tissues and neoplasms, and has become a defining immunohistochemical feature of chordoma. The main differential diagnostic consideration for chordoma is chondrosarcoma, which is known to lack brachyury expression. However, within the spectrum of genitourinary neoplasia, metastatic germ cell tumors and clear cell renal cell carcinoma may also be close morphological mimics of chordoma, particularly given the increasing prevalence of small tissue samples from image-guided biopsies. Although immunoreactivity for brachyury has been reported in a few germ cell tumors, a thorough characterization of staining by specific subtype has not been performed in a large series. Additionally, brachyury expression in clear cell renal cell carcinoma has not been well studied. In this study, immunohistochemical expression with the brachyury antibody was evaluated in 111 germ cell tumors, 30 non-neoplastic and neoplastic (non-germ cell) testicular tissues, and 184 metastatic clear cell renal cell carcinomas using tissue microarray technology. In addition, immunoreactivity for PAX-8 and SALL-4 was evaluated in 12 chordomas on whole section. No nuclear brachyury expression was identified in any of the 101 germ cell tumors within the tissue microarray (including choriocarcinoma (1), embryonal carcinoma (20), intratubular germ cell neoplasia unclassified (2), seminoma (64), spermatocytic seminoma (1), teratoma (5) and yolk sac tumor (8)), in any of the 30 non-neoplastic and neoplastic (non-germ cell) testicular tissues, or in any of the 10 whole-section seminomas. All 184 metastatic clear cell renal cell carcinomas were also non-reactive for brachyury. All 12 chordomas showed strong nuclear immunoreactivity for brachyury, but no expression of SALL-4. In all, 1 of 12 chordoma cases showed patchy, 1+ nuclear immunoreactivity for PAX-8. This study confirms the specificity of brachyury for chordoma in the differential diagnostic distinction from the potential genitourinary mimics, germ cell tumors and metastatic clear cell renal cell carcinoma.
Brachyury 被认为是脊索源性组织和肿瘤的特异性标志物,已成为脊索瘤的免疫组织化学特征。脊索瘤的主要鉴别诊断考虑因素是软骨肉瘤,已知软骨肉瘤缺乏 brachyury 表达。然而,在泌尿生殖系统肿瘤谱中,转移性生殖细胞肿瘤和透明细胞肾细胞癌也可能与脊索瘤形态相似,特别是由于越来越多的小组织样本来自影像学引导的活检。尽管已有少数生殖细胞肿瘤报道 brachyury 的免疫反应性,但尚未在大型系列中对特定亚型的染色进行全面特征描述。此外,透明细胞肾细胞癌中 brachyury 的表达尚未得到很好的研究。在这项研究中,使用组织微阵列技术评估了 brachyury 抗体在 111 个生殖细胞肿瘤、30 个非肿瘤和肿瘤(非生殖细胞)睾丸组织以及 184 个转移性透明细胞肾细胞癌中的表达。此外,还在 12 个整块切片的脊索瘤中评估了 PAX-8 和 SALL-4 的免疫反应性。在组织微阵列中的 101 个生殖细胞肿瘤(包括绒毛膜癌(1)、胚胎癌(20)、未分类的小管内生殖细胞肿瘤(2)、精原细胞瘤(64)、精原细胞性精原细胞瘤(1)、畸胎瘤(5)和卵黄囊瘤(8))、30 个非肿瘤和肿瘤(非生殖细胞)睾丸组织或 10 个整块精原细胞瘤中,均未发现核 brachyury 表达。所有 184 个转移性透明细胞肾细胞癌也均无 brachyury 反应。所有 12 个脊索瘤均显示强烈的核 brachyury 免疫反应性,但无 SALL-4 表达。在所有 12 个脊索瘤病例中,有 1 例显示斑片状、1+核 PAX-8 免疫反应性。这项研究证实了 brachyury 在鉴别诊断中的特异性,可将其与潜在的泌尿生殖系统模拟物、生殖细胞肿瘤和转移性透明细胞肾细胞癌区分开来。